Akeega (niraparib and abiraterone acetate tablets – Janssen Biotech) — Cigna
Prostate cancer – metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious BRCA mutation
Initial criteria
- Patient is age ≥ 18 years; AND
- Patient has metastatic castration-resistant prostate cancer; AND
- Patient has a BRCA mutation; AND
- Medication is used in combination with prednisone; AND
- Patient meets ONE of the following (i or ii):
- i. Medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog (examples: leuprolide acetate, Lupron Depot, Trelstar, Zoladex, Vantas, Firmagon, Orgovyx); OR
- ii. Patient has had a bilateral orchiectomy.
Approval duration
1 year